Business Context and Reporting Period
Company: Milestone Scientific Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Milestone Scientific develops and markets proprietary Computer-Controlled Local Anesthesia Delivery (C-CLAD) solutions, primarily the STA System and CompuDent, for the dental and medical industries. The company operates as a smaller reporting company and has incurred operating losses since inception.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2008 |
|---|---|---|---|
| Total Revenue | $1,909,263 | $6,150,984 | $4,770,258 |
| Gross Profit | $1,200,260 (63% margin) | $3,662,690 (60% margin) | $2,971,500 (62% margin) |
| Net Loss | $(373,270) | $(1,591,454) | $(1,275,735) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.12) | $(0.10) |
| Cash and Cash Equivalents | $497,455 (as of Sep 30, 2009) | ||
| Working Capital | |||
| Working Capital | $(406,968) (Negative) | ||
| Total Debt (Line of Credit + Notes) | $1,709,168 (Net of discounts) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 29% for the nine months ended September 30, 2009, compared to the prior year. This was driven by a 38% increase in international revenue and a 26% increase in domestic revenue.
- Product Mix Shift: Sales of the STA System units increased significantly ($1.27 million increase in nine-month period), while CompuDent handpiece sales decreased. International unit sales grew 87% year-over-year.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 23% to $4.96 million for the nine-month period. Increases were attributed to marketing, trade shows, a new international sales commission structure, and consulting fees paid in stock.
- Net Loss Expansion: Net loss increased by 25% to $1.59 million for the nine-month period, primarily due to higher operating expenses and interest costs, despite revenue growth.
- Working Capital Deterioration: Working capital turned negative ($406,968) from a positive position in 2008. This is largely due to the reclassification of a $1.3 million line of credit from long-term to current liability as it matures on June 30, 2010.
Guidance, Outlook, and Risks
- Going Concern: The company explicitly states that recurring losses and negative operating cash flows raise substantial doubt about its ability to continue as a going concern. Management expects sufficient cash reserves to meet obligations only through December 31, 2009.
- Liquidity Strategy: The company is actively pursuing positive cash flows through revenue increases and expense reductions. If capital cannot be raised, the company may be forced to curtail development or marketing activities.
- Debt Obligations: A $1.3 million line of credit from a stockholder is due June 30, 2010. Repayment can be made in cash or, at the company's option, in shares of common stock. An additional $450,000 note is due June 30, 2012.
- Strategic Changes: Effective July 1, 2009, the company began selling directly to international distributors rather than through a master distributor, resulting in higher recorded sales but also a new commission obligation ($117,790 in Q3).
- Subsequent Events: Post-quarter, the company received a blanket purchase order for 12,000 STA Systems from Sinopharm (China) deliverable over 36 months. A new CEO bonus program tied to Sinopharm revenue targets was also established.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured additional financing to bridge the gap beyond December 31, 2009, given the "substantial doubt" disclosure.
- Debt Conversion Terms: Review the specific terms for converting the $1.3 million line of credit into equity, including the conversion price formula (lower of $2.00 or 80% of average closing price).
- Sinopharm Order Execution: Monitor the fulfillment and revenue recognition of the 12,000 unit order from Sinopharm announced as a subsequent event.
- Stock-Based Compensation: Assess the impact of significant stock issuances for services and compensation (approx. $787,000 in non-cash expenses for the nine months) on future dilution.
- International Commission Structure: Confirm the long-term impact of the new commission agreement with the former master distributor on gross margins.